Boryung (003850.KS) Stock Price

Boryung Price

KOSDAQ·CLOSED
9,170.00KRW+10.00 (+0.11 %)
Market closed

Over the last 19 years Boryung grew revenue by 10.3% annually, reaching 1.02 T KRW. Earnings per share have grown at 15.9% per year over the last 19 years. For Boryung, the net margin of 6.8% is up versus 4.8% a few years ago. At today's price the dividend yield works out to roughly 1.09%. The payout ratio is around 10% of earnings. The consensus 12-month price target for Boryung is 12,240.00 KRW, about 33.5% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 19% above its 52-week low.

Boryung stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Boryung over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Boryung stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Boryung's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Boryung Stock Price History
DateBoryung Price
8/14/20269,170.00 KRW
8/13/20269,160.00 KRW
8/12/20269,190.00 KRW
8/11/20269,230.00 KRW
8/10/20269,100.00 KRW
8/7/20268,800.00 KRW
8/6/20268,780.00 KRW
8/5/20268,560.00 KRW
8/4/20268,350.00 KRW
8/3/20268,250.00 KRW
7/31/20268,040.00 KRW
7/30/20267,850.00 KRW
7/29/20267,690.00 KRW
7/28/20267,970.00 KRW
7/27/20268,240.00 KRW
7/24/20268,250.00 KRW
7/23/20268,080.00 KRW
7/22/20267,970.00 KRW
7/21/20268,130.00 KRW
7/20/20268,210.00 KRW
7/16/20268,300.00 KRW
7/15/20268,220.00 KRW
7/14/20268,030.00 KRW
7/13/20268,420.00 KRW
7/10/20268,470.00 KRW
7/9/20268,110.00 KRW
7/8/20268,210.00 KRW
7/7/20268,430.00 KRW
7/6/20268,400.00 KRW
7/3/20268,420.00 KRW
7/2/20268,420.00 KRW
7/1/20268,550.00 KRW
6/30/20268,480.00 KRW
6/29/20268,620.00 KRW
6/26/20268,050.00 KRW
6/25/20268,570.00 KRW
6/24/20268,440.00 KRW
6/23/20268,280.00 KRW
6/22/20268,830.00 KRW
6/19/20268,990.00 KRW
6/18/20269,140.00 KRW
6/17/20269,570.00 KRW
6/16/20269,460.00 KRW
6/15/20269,270.00 KRW
6/12/20268,760.00 KRW
6/11/20268,400.00 KRW
6/10/20268,250.00 KRW
6/9/20268,340.00 KRW
6/8/20267,920.00 KRW
6/5/20268,350.00 KRW
6/4/20268,560.00 KRW
6/2/20268,610.00 KRW
6/1/20268,720.00 KRW
5/29/20269,020.00 KRW
5/28/20269,130.00 KRW
5/27/20269,300.00 KRW
5/26/20269,430.00 KRW
5/22/20269,650.00 KRW
5/21/20269,410.00 KRW
5/20/20269,250.00 KRW
5/19/20269,590.00 KRW
5/18/20269,460.00 KRW
5/15/20269,700.00 KRW
5/14/20269,880.00 KRW
5/13/20269,410.00 KRW
5/12/20269,520.00 KRW
5/11/20269,420.00 KRW
5/8/20269,620.00 KRW
5/7/20269,660.00 KRW
5/6/20269,760.00 KRW
5/4/202610,010.00 KRW
4/30/20269,940.00 KRW
4/29/202610,080.00 KRW
4/28/202610,050.00 KRW
4/27/20269,980.00 KRW
4/24/202610,170.00 KRW
4/23/20269,810.00 KRW
4/22/20269,820.00 KRW
4/21/20269,880.00 KRW
4/20/202610,160.00 KRW
4/17/202610,220.00 KRW
4/16/202610,200.00 KRW
4/15/202610,050.00 KRW
4/14/202610,000.00 KRW
4/13/20269,570.00 KRW
4/10/20269,760.00 KRW
4/9/20269,680.00 KRW
4/8/20269,730.00 KRW
4/7/20269,400.00 KRW
4/6/20269,110.00 KRW
4/3/20269,130.00 KRW
4/2/20269,040.00 KRW
4/1/20269,530.00 KRW
3/31/20269,000.00 KRW
3/30/20269,230.00 KRW
3/27/20269,650.00 KRW
3/26/20269,660.00 KRW
3/25/20269,400.00 KRW
3/24/20269,100.00 KRW
3/23/20269,030.00 KRW
3/20/20269,370.00 KRW
3/19/20269,300.00 KRW
3/18/20269,420.00 KRW
3/17/20269,410.00 KRW
3/16/20269,340.00 KRW
3/13/20269,590.00 KRW
3/12/20269,450.00 KRW
3/11/20269,480.00 KRW
3/10/20269,210.00 KRW
3/9/20269,120.00 KRW
3/6/20269,470.00 KRW
3/5/20269,490.00 KRW
3/4/20268,750.00 KRW
3/3/20269,810.00 KRW
2/27/20269,950.00 KRW
2/26/202610,070.00 KRW
2/25/202610,190.00 KRW
2/24/202610,370.00 KRW
2/23/202610,200.00 KRW
2/20/202610,350.00 KRW
2/19/202610,680.00 KRW
2/13/20269,460.00 KRW
2/12/20269,560.00 KRW
2/11/20269,670.00 KRW
2/10/20269,540.00 KRW
2/9/20269,360.00 KRW
2/6/20269,300.00 KRW
2/5/20269,430.00 KRW
2/4/20269,790.00 KRW
2/3/20269,620.00 KRW
2/2/20268,970.00 KRW
1/30/20269,250.00 KRW
1/29/20269,280.00 KRW
1/28/20269,160.00 KRW
1/27/20269,180.00 KRW
1/26/20269,400.00 KRW
1/23/20269,190.00 KRW
1/22/20268,930.00 KRW
1/21/20268,770.00 KRW
1/20/20269,010.00 KRW
1/19/20268,770.00 KRW
1/16/20268,700.00 KRW
1/15/20268,610.00 KRW
1/14/20268,540.00 KRW
1/13/20268,650.00 KRW
1/12/20268,770.00 KRW
1/9/20268,810.00 KRW
1/8/20268,880.00 KRW
1/7/20269,160.00 KRW
1/6/20269,300.00 KRW
1/5/20269,300.00 KRW
1/2/20269,350.00 KRW
12/30/20259,010.00 KRW
12/29/20258,990.00 KRW
12/26/20259,020.00 KRW
12/24/20259,150.00 KRW
12/23/20259,290.00 KRW
12/22/20259,360.00 KRW
12/19/20259,250.00 KRW
12/18/20259,080.00 KRW
12/17/20259,340.00 KRW
12/16/20259,270.00 KRW
12/15/20259,130.00 KRW
12/12/20259,190.00 KRW
12/11/20259,190.00 KRW
12/10/20259,180.00 KRW
12/9/20259,230.00 KRW
12/8/20259,020.00 KRW
12/5/20259,030.00 KRW
12/4/20259,040.00 KRW
12/3/20259,150.00 KRW
12/2/20259,050.00 KRW
12/1/20258,950.00 KRW
11/28/20258,940.00 KRW
11/27/20258,660.00 KRW
11/26/20258,610.00 KRW
11/25/20258,240.00 KRW
11/24/20258,180.00 KRW
11/21/20258,320.00 KRW
11/20/20258,500.00 KRW
11/19/20258,430.00 KRW
11/18/20258,490.00 KRW
11/17/20258,760.00 KRW
11/14/20258,750.00 KRW
11/13/20258,880.00 KRW
11/12/20258,870.00 KRW
11/11/20258,640.00 KRW
11/10/20258,750.00 KRW
11/7/20258,610.00 KRW
11/6/20258,960.00 KRW
11/5/20258,950.00 KRW
11/4/20258,970.00 KRW
11/3/20258,870.00 KRW
10/31/20258,830.00 KRW
10/30/20258,840.00 KRW
10/29/20258,900.00 KRW
10/28/20258,840.00 KRW
10/27/20258,790.00 KRW
10/24/20258,530.00 KRW
10/23/20258,540.00 KRW
10/22/20258,610.00 KRW
10/21/20258,580.00 KRW
10/20/20258,540.00 KRW
10/17/20258,330.00 KRW
10/16/20258,390.00 KRW
10/15/20258,360.00 KRW
10/14/20258,360.00 KRW
10/13/20258,380.00 KRW
10/10/20258,490.00 KRW
10/2/20258,590.00 KRW
10/1/20258,790.00 KRW
9/30/20258,720.00 KRW
9/29/20258,740.00 KRW
9/26/20258,420.00 KRW
9/25/20258,560.00 KRW
9/24/20258,690.00 KRW
9/23/20258,830.00 KRW
9/22/20258,850.00 KRW
9/19/20258,710.00 KRW
9/18/20258,650.00 KRW
9/17/20258,660.00 KRW
9/16/20258,720.00 KRW
9/15/20258,670.00 KRW
9/12/20258,610.00 KRW
9/11/20258,600.00 KRW
9/10/20258,610.00 KRW
9/9/20258,670.00 KRW
9/8/20258,660.00 KRW
9/5/20258,590.00 KRW
9/4/20258,430.00 KRW
9/3/20258,380.00 KRW
9/2/20258,250.00 KRW
9/1/20258,180.00 KRW
8/29/20258,350.00 KRW
8/28/20258,350.00 KRW
8/27/20258,360.00 KRW
8/26/20258,310.00 KRW
8/25/20258,270.00 KRW
8/22/20258,200.00 KRW
8/21/20258,220.00 KRW
8/20/20258,210.00 KRW
8/19/20258,300.00 KRW
8/18/20258,470.00 KRW
Access this data via the Eulerpool API
Get Free API Key

Boryung Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
627.28 B KRW
41.45 B KRW
43.04 B KRW
Jan 1, 2022
760.48 B KRW
56.60 B KRW
41.89 B KRW
Jan 1, 2023
859.63 B KRW
68.27 B KRW
40.20 B KRW
Jan 1, 2024
1.02 T KRW
70.47 B KRW
69.63 B KRW
Jan 1, 2025 (e)
1.04 T KRW
79.03 B KRW
28.43 B KRW
Jan 1, 2026 (e)
1.06 T KRW
80.71 B KRW
52.89 B KRW
Jan 1, 2027 (e)
1.08 T KRW
82.73 B KRW
54.46 B KRW
Jan 1, 2028 (e)
1.13 T KRW
86.14 B KRW
62.48 B KRW

Boryung Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 16, 2026, 4:04 PM
 
REVENUET KRW
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB KRW
EBITB KRW
EBIT MARGIN%
NET INCOMEB KRW
NET INCOME GROWTH%
DIV.KRW
DIV. GROWTH%
SHARESM
2013201420152016201720182019202020212022202320242025e2026e2027e2028e
0.330.360.400.410.420.460.520.560.630.760.861.021.041.061.081.13
4.879.8411.641.943.328.9113.877.1711.6421.2313.0418.321.822.132.514.12
43.0644.5542.1043.1739.7040.9742.5341.1942.2440.3941.1135.7235.7235.7235.7235.72
140.93160.17168.99176.61167.82188.61223.00231.44264.94307.19353.43363.36369.96377.86387.32403.29
19.1424.4427.5522.021.0224.9639.0639.9941.4556.6068.2770.4779.0380.7182.7386.14
5.856.806.865.380.245.427.457.126.617.447.946.937.637.637.637.63
14.1321.5920.305.6156.7020.3132.2226.8643.0441.8940.2069.6328.4352.8954.4662.48
50.2752.83-5.97-72.35909.96-64.1858.67-16.6560.28-2.67-4.0473.21-59.1786.032.9814.72
142.82190.43190.46190.36800.0060.00100.0090.93100.00100.00100.00100.00100.00106.12112.62–
-0.0233.340.02-0.05320.26-92.5066.67-9.079.97––––6.126.13–
48.0048.0048.0048.0050.0047.0047.0050.0063.0365.8865.9368.5168.5168.5168.5168.51
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Boryung generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Boryung retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Boryung's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Boryung has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Boryung's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Boryung stock margins

The Boryung margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Boryung. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Boryung.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
41.19 %
7.12 %
4.78 %
Jan 1, 2021
42.24 %
6.61 %
6.86 %
Jan 1, 2022
40.39 %
7.44 %
5.51 %
Jan 1, 2023
41.11 %
7.94 %
4.68 %
Jan 1, 2024
35.72 %
6.93 %
6.85 %
Jan 1, 2025 (e)
35.72 %
7.63 %
2.75 %
Jan 1, 2026 (e)
35.72 %
7.63 %
5.00 %
Jan 1, 2027 (e)
35.72 %
7.63 %
5.02 %

Boryung Stock Revenue, EBIT, Earnings per Share

The Boryung earnings per share therefore indicates how much revenue Boryung has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
11,237.34 KRW
799.72 KRW
537.12 KRW
Jan 1, 2021
9,952.30 KRW
657.61 KRW
682.93 KRW
Jan 1, 2022
11,543.12 KRW
859.16 KRW
635.91 KRW
Jan 1, 2023
13,038.22 KRW
1,035.43 KRW
609.77 KRW
Jan 1, 2024
14,846.24 KRW
1,028.65 KRW
1,016.40 KRW
Jan 1, 2025 (e)
15,116.17 KRW
1,153.49 KRW
415.00 KRW
Jan 1, 2026 (e)
15,438.76 KRW
1,178.11 KRW
772.00 KRW
Jan 1, 2027 (e)
15,825.57 KRW
1,207.63 KRW
795.00 KRW

Boryung business model & stock analysis

Boryung Corp is a South Korean company that was founded in 1963 and is headquartered in Seoul. The founders are In-Bum Kim and Myung-Chul Kang. The company is very successful in the pharmaceutical and cosmetic industries. It has a leading position in the prescription drug market and has also specialized in the development and marketing of over-the-counter products. History: Boryung Corp has experienced impressive growth in various areas over the past decades. The company's original focus was the production of pharmaceutical products for the local healthcare industry. Thanks to hard work and large investments, Boryung began to succeed in international markets for pharmaceutical products. The company expanded its business operations by establishing a branch for cosmetic products as well as food and beverage production. Business model: Boryung Corp's business model is based on marketing medical products for domestic and international markets, as well as developing and marketing cosmetics and dietary supplements. The company sells its products under various brands, including Valtocin (for high blood pressure), Eumosone (for skin conditions), and Rapithon (for colds). The company aims to make its brands synonymous with quality and effectiveness in the markets where it operates. Various divisions: Boryung Corp has various divisions and subsidiaries specializing in different categories of products. The company operates a branch for cosmetic products (known as K-beauty). Notable cosmetic brands of Boryung include Mizon (skin care products), AHC (high-quality cosmetics), and Ryo (hair care series). The company also produces high-quality food and beverages, including soy products, instant noodles, and energy drinks. Products: Boryung offers a wide range of products, including prescription drugs, over-the-counter medications, consumer goods, and cosmetics. The company's prescription drugs are in high demand and include a wide range of products such as antibiotics, antidiabetic drugs, antihypertensives, as well as medications for skin diseases, cancer, and diabetes. Boryung is also very active in product-related research and development, investing a significant portion of its revenue in research and development. Conclusion: Boryung Corp has repeatedly proven over the years that it is an extremely versatile and successful company operating in a variety of business sectors. The company has established a strong position in the prescription drug and cosmetic product markets and is also involved in other business areas. Through continuous research and development of new products and the expansion of existing product lines, the company is driving its growth forward.

Boryung SWOT Analysis

Strengths

Boryung Corp has built a strong reputation in the market due to its commitment to quality and innovation. This reputation helps the company gain customer trust and loyalty.

With a wide range of products across various therapeutic areas, Boryung Corp has a diversified product portfolio that reduces dependency on a single product or market segment.

Weaknesses

Boryung Corp's operations are primarily concentrated in the domestic market, limiting its global reach and potential for international growth.

The company heavily relies on a few key markets for a significant portion of its revenue, making it vulnerable to market-specific risks and fluctuations.

Opportunities

Expanding into emerging markets presents an opportunity for Boryung Corp to tap into growing customer demand and potentially increase its market share.

Leveraging advancements in technology can enable Boryung Corp to develop innovative products, improve operational efficiency, and gain a competitive edge in the industry.

Threats

The pharmaceutical industry is highly competitive, and Boryung Corp faces threats from existing competitors as well as new entrants in the market.

Compliance with stringent regulations and changing government policies poses a threat to Boryung Corp's operations, requiring constant monitoring and adaptation.

Boryung Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Boryung historical P/E ratio, EBIT multiple, and P/S ratio

Boryung annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Boryung shares outstanding

The number of shares of Boryung was 68.51 M in 2025. This indicates how many shares Boryung is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
50.00 M Stocks
Jan 1, 2021
63.03 M Stocks
Jan 1, 2022
65.88 M Stocks
Jan 1, 2023
65.93 M Stocks
Jan 1, 2024
68.51 M Stocks
Jan 1, 2025 (e)
68.51 M Stocks
Jan 1, 2026 (e)
68.51 M Stocks
Jan 1, 2027 (e)
68.51 M Stocks

Boryung stock splits

In Boryung's history, there have been no stock splits.

Boryung Dividend History

35 years of dividend payments

YearAnnual DividendYoY ChangePayments
2024100.00KRW 0.0%1×
2023100.00KRW 0.0%1×
2022100.00KRW 0.0%1×
2021100.00KRW↑ 10.0%1×
202090.93KRW↓ 9.1%1×
2019100.00KRW↑ 66.7%1×
201860.00KRW↓ 92.5%1×
2017800.00KRW↑ 320.3%1×
2016190.36KRW↓ 0.1%1×
2015190.46KRW↑ 0.0%1×

Boryung dividend history and estimates

In 2025, Boryung paid a dividend amounting to 100.00 KRW. Dividend means that Boryung distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2020
90.93 KRW
0.00 KRW
Jan 1, 2021
100.00 KRW
0.00 KRW
Jan 1, 2022
100.00 KRW
0.00 KRW
Jan 1, 2023
100.00 KRW
0.00 KRW
Jan 1, 2024
100.00 KRW
0.00 KRW
Jan 1, 2025
100.00 KRW
0.00 KRW
Jan 1, 2026 (e)
0.00 KRW
106.12 KRW
Jan 1, 2027 (e)
0.00 KRW
112.62 KRW

Boryung dividend payout ratio

In 2025, Boryung had a payout ratio of 24.10%. The payout ratio indicates the percentage of the company's profits that Boryung distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
13.83 %
Jan 1, 2021
14.64 %
Jan 1, 2022
15.73 %
Jan 1, 2023
16.40 %
Jan 1, 2024
9.84 %
Jan 1, 2025 (e)
24.10 %
Jan 1, 2026 (e)
13.75 %
Jan 1, 2027 (e)
14.17 %

Current Boryung forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
12,240.00
Last Price
9,170.00
Currency
KRW
12M Return Potential
33.48 %
LTM Return
0 %

Boryung shareholder structure

% Name
1.13722%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.67354%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
0.64741%
Kim (Seong Jin)
Kim (Seong Jin)
0.59042%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
0.24349%
Mirae Asset Global Investments Co., Ltd.
Mirae Asset Global Investments Co., Ltd.
0.17161%
Park (Yun Sik)
Park (Yun Sik)

Boryung Beneficial Ownership Filings (SEC 13D/G)

Free Float
33.7%
Float Shares
-
Shares Outstanding
-

Boryung Executives and Management Board

28 members · avg. age 52 · 18 % women

SK

Mr. Seong Kim (37)

Chief Strategy Officer, Director

603.91 M KRW

Management

JK

Mr. Jeong Gyun Kim (39)

Chairman of the Board, Chief Executive Officer · since 2025

563.15 M KRW
JY

Mr. Jong Rae Yim (55)

Vice President

–
MB

Mr. Min Je Bae (57)

Managing Director

–
SC

Mr. Seong Won Choi (41)

Managing Director

–
WJ

Mr. Wung Je Jung (55)

Managing Director

–
BK

Mr. Bong Seok Kim (56)

Managing Director

–

Board of Directors

EK

Ms. Eun Seon Kim (64)

Director

–
TC

Mr. Tae Jin Cha (58)

Non-Executive Independent Director

–
YP

Mr. Yin Ho Park (60)

Non-Executive Independent Director

–

Frequently asked questions about Boryung

The business model of Boryung Corp is focused on pharmaceuticals and healthcare products. Boryung Corp operates as a global biopharmaceutical company, dedicated to developing, manufacturing, and distributing high-quality medications and healthcare solutions. With a strong emphasis on research and development, Boryung Corp strives to discover innovative drugs and treatments to improve the quality of life for patients worldwide. By leveraging its expertise and advanced technologies, Boryung Corp aims to address various medical needs, ranging from chronic diseases to infectious conditions, ultimately contributing to the overall well-being of individuals and communities.

Boryung Corp is primarily active in the pharmaceutical industry.

Boryung Corp faces tough competition from several major players in the market. Some of its main competitors include multinational pharmaceutical companies like Pfizer, Merck, and Novartis. These companies, along with others in the industry, vie for market share and strive to develop innovative pharmaceutical products and expand their global presence. Boryung Corp competes with these well-established players by leveraging its expertise in research and development, focusing on product differentiation, and maintaining strong customer relationships.

Boryung Corp, established in 1963, is a renowned South Korean pharmaceutical company. With a strong focus on research and development, Boryung Corp has grown into a global player in the healthcare industry. The company's diverse portfolio includes prescription drugs, over-the-counter medications, and healthcare products. Boryung Corp has achieved significant milestones in the treatment of various diseases, providing innovative solutions to improve patient outcomes. Through strategic collaborations and investments in cutting-edge technology, Boryung Corp continues to expand its presence in both domestic and international markets. With a rich history and a commitment to advancing healthcare, Boryung Corp remains a trusted name in the pharmaceutical sector.

Boryung Corp has achieved several significant milestones throughout its history. One of the notable achievements includes the development and commercialization of innovative pharmaceutical products. The company has also established a strong presence in the global market by expanding its business operations and collaborations with international partners. Boryung Corp has consistently focused on research and development, leading to breakthroughs and advancements in the healthcare industry. Additionally, the company has been recognized for its commitment to high-quality products and has received various prestigious awards and certifications. Overall, Boryung Corp has demonstrated its dedication to innovation, global growth, and excellence in the pharmaceutical sector.

Boryung Corp is primarily present in South Korea.

Boryung Corp represents a strong set of values and corporate philosophy. The company is dedicated to innovation, excellence, and ethical business practices. With a focus on customer satisfaction, Boryung Corp strives to provide high-quality products and services that meet the diverse needs of its consumers. The company also values sustainability and social responsibility, aiming to make a positive impact on the community and the environment. Boryung Corp's commitment to continuous improvement and proactive strategies has enabled it to establish a reputable presence in the market. Overall, Boryung Corp's values and corporate philosophy are centered around delivering value, fostering growth, and prioritizing the well-being of its stakeholders.

Analysts currently set an average price target of 12,240.00 KRW for the Boryung stock (median: 12,240.00 KRW), implying +33.5 % versus the latest price. The consensus is based on 5 analyst ratings.

Boryung Analyst Price Targets 2026

5 analysts currently rate the Boryung stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Boryung to generate revenue of 1.06 T KRW and earnings per share of 772.00 KRW.

Boryung Analyst Price Targets 2026

Converted at the current exchange rate, the Boryung share trades at 5.61 EUR (9,170.00 KRW).

Boryung Corporation is a Korean company that was founded in 1963 and has been active in various industries since then. The company is headquartered in Seoul and operates in the healthcare, chemical, and biotechnology sectors. In the healthcare sector, Boryung Corp is one of the leading manufacturers of pharmaceuticals in the Korean market. The company specializes in the development and manufacturing of drugs for the treatment of serious diseases such as cancer, diabetes, and cardiovascular diseases. Some of Boryung Corp's most well-known products include the antiviral agent Arvirargen, used in the treatment of influenza, and the cardiological preparation Nitomel, used in the treatment of heart failure. In the chemical sector, Boryung Corp is involved in the production of petrochemical products such as refinery products and polymeric materials. The company also operates a production facility for plastic parts and plastic films, which are used in various industries such as automotive, packaging, and electronics. Boryung Corp is also heavily involved in the biotechnology sector and is developing therapeutic antibodies and immuno-oncological therapies to treat various types of cancer. The company has an exclusive licensing agreement with US-based company OncoMed Pharmaceuticals to enhance the development and commercialization of cancer drugs. An important pillar of Boryung Corp's business model is research and development. The company invests approximately 10% of its revenue annually in research and has its own research facility specializing in biotechnology. In collaboration with other companies, universities, and research institutions in Korea and worldwide, Boryung Corp has demonstrated its ability to develop innovative products and solutions that transform the market. Another important aspect of Boryung Corp's business model is its globally-oriented strategy. The company has a strong presence in the Korean market, but is also expanding into new markets worldwide. Through collaborations with other companies and local trade partners, Boryung Corp has built a strong international presence and operates in over 50 countries. Overall, Boryung Corp's business model is focused on developing and producing innovative solutions in various industries. The company specializes in the manufacturing of high-quality products and heavily invests in research and development to grow in new markets. With its global orientation and wide range of products and services, Boryung Corp is an important player in various industries and a company that is focused on its continuous growth.

The expected revenue of Boryung is 1.06 T KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Boryung is 52.89 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Boryung is currently 11.88. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Boryung stock.

The price-to-sales ratio (P/S) of Boryung is currently 0.59. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Boryung stock.

The Eulerpool Quality Score for Boryung is 7/10.

The ISIN of Boryung is KR7003850005. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Boryung is 003850.KS. The ticker symbol is used to trade Boryung shares on the stock exchange.

Over the past 12 months, Boryung paid a dividend of 100.00 KRW . This corresponds to a dividend yield of about 1.09 %. For the coming 12 months, Boryung is expected to pay a dividend of 112.62 KRW.

The current dividend yield of Boryung is 1.09 %.

Boryung pays a dividend, distributed in the months of , , , .

Boryung paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 112.62 KRW are expected. This corresponds to a dividend yield of 1.23 %.

Boryung is assigned to the 'Health' sector.

To receive the latest dividend of Boryung from amounting to 100 KRW, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Boryung distributed 100 KRW as dividends.

The dividends of Boryung are distributed in KRW.

All fundamentals and in-depth analysis of Boryung

Our stock analysis for Boryung stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Boryung. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Boryung Stock
Boryung Revenue→
Boryung Stock
Boryung Net Income→
Boryung Stock
Boryung P/E→
Boryung Stock
Boryung P/S→
Boryung Stock
Boryung EBIT→
Boryung Stock
Boryung Dividend→
Boryung Stock
Boryung Directors Dealings→
Boryung Stock
Boryung Stocks→
Boryung Stock
Boryung Market capitalization→
Boryung Stock
Boryung Debt→
Boryung Stock
Boryung Liabilities→
Boryung Stock
Boryung Equity→
Boryung Stock
Boryung AAQS→
Boryung Stock
Boryung Employees→
Boryung Stock
Boryung ROE→
Boryung Stock
Boryung ROA→
Boryung Stock
Boryung ROCE→
Boryung Stock
Boryung News→
Boryung Stock
Boryung Analyst Price Targets→

Health Stocks

Boston ScientificBorosil ScientificBotanix PharmaceuticalsBonus BiogroupBoule DiagnosticsBonraybio CoBoundless BioBonesupport HoldingBPH EnergyBone BiologicsBPH GlobalBolt BiotherapeuticsAll Stocks A–Z →